1. Customized Oncology
Development Solutions
Clinical Trials Designed Around You®
Oncology is one of the most research-intensive therapeutic areas, yet no two
development programs are the same. No two trials are the same. Each one calls for
a customized strategy and distinct trial management approach. Covance develops
fit-for-purpose solutions Designed Around You®
that enable more efficient clinical
trials and focus on what is most valuable to your organization.
Tap the largest single source of patient lab data to understand
your trial’s feasibility and identify eligible patients – before
they’re placed on the standard of care.
 Consult diagnosis codes, genomic data and specific
biomarkers, representing ~50% of the U.S. population
 Locate clusters of potential patients, including pediatric and
rare disease areas
 Access direct-to-patient outreach to improve protocol design
Accelerate Patient Recruitment with Unique, Proprietary Data
Access Scientific Depth in Precision Medicine
The individualized nature of cancers makes drug development
costly, complex and risky. Advanced tools and scientific advice from
industry experts improve the probability of success.
 Consult with our scientific experts in cell and gene therapies,
autologous/allogenic CAR-T and checkpoint inhibitors
 Rely on our experience in biomarkers, companion diagnostics
and genomics
 Advance your programs across early clinical to late stage, in
many niche areas including pediatrics and rare diseases
Select Sites with the Right Patients, Experience and Track Record
Investigator site performance data from Covance Central Labs
generates more trial data than anyone else in the world and
identifies the most ideal investigators for your study.
 Draw on insights from ~50% of global clinical trials, more
than 175,000 investigators and more than 15,000 protocols in
102 countries
 Lever relationships with the right institutions around the
globe relevant to your development program
 Collaborate with local and international KOLs, global
collaborative groups and patient networks
INSIGHTS ON
30+ BILLION
TEST RESULTS
FOR OVER
150 MILLION
PEOPLE IN THE U.S.
65% OF ALL
FDA-APPROVED CDx
ASSAYS ON THE MARKET
792
PATIENTS
13
STUDIES
16 months
12 months
INDUSTRY
COVANCE
SAVE 4.2 MONTHS
SITE ACTIVATION TO LAST
PATIENT IN - GLOBAL
CAR-T (PAST 5 YEARS)
203
SITES

2. The ability to make go/no-go decisions and the
flexibility to adapt to changing requirements are
hallmarks of successful trials for innovative and
complex products.
 Create an optimal strategy to develop your assets
to achieve their specific goal
 Address changes in the global regulatory
environment with knowledge of local
requirements and extended review timelines
 Depend on our expertise in basket, umbrella
and/or adaptive designs
Surprises extend timelines and break budgets. Our professionals have extensive experience in all tumor types and
hematologic oncology and meet rigorous training requirements that keep your trial on track.
 Ensure faster and higher quality trial delivery with Xcellerate®
informatics real-time data
 Access matrixed specialists across a variety of indications and therapy modalities, including complex combination trials
and expertise in immunotherapies and rare oncology indications
 Deliver robust investigator site support with detailed communication, protocol comprehension and procedural guidelines
Navigating the Regulatory Landscape
Meet Your Milestones, on Budget, with a Highly Experienced Project Team
To learn more about how Covance can help you meet the challenges in developing
oncology therapies and delivering them to market quickly and cost effectively,
please contact us at www.covance.com
Covance is the drug, medical device and diagnostics business segment of LabCorp, a leading
global life sciences company. COVANCE is a registered trademark and the marketing name for
Covance Inc. and its subsidiaries around the world.
The Americas + 1.888.COVANCE (+1.888.268.2623) + 1.609.452.4440
Europe / Africa + 00.800.2682.2682 +44.1423.500888
Asia Pacific + 800.6568.3000 +65.6.5686588
© Copyright 2019 Covance Inc. SSCDS095-0519
ADAPTIVE TRIAL DESIGN
EXPERIENCE (PAST 5 YEARS)
HEMATOLOGIC (12 Studies)
SOLID (36 Studies)
ONCOLOGY EXPERIENCE (PAST 5 YEARS)
731
STUDIES
112,646
PATIENTS
21,132
SITES
74
COUNTRIES
55%
Phase I
28%
Phase I/II
17%
Phase II
33% 42% 25%
Phase I Phase I/II Phase II
Hematologic
and Solid
SolidHematologic
31%
14%
21% 22%
3% 5%
3% 9%
65%
26%
Phase I Phase I–II Phase II Phase III Phase IV Multiple Device
and
Diagnostic